These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 30531606

  • 1. Antibody-drug conjugates for ovarian cancer: current clinical development.
    Stewart D, Cristea M.
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
    [Abstract] [Full Text] [Related]

  • 2. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, Themeles M, Zhou Y, Pinkas J, Ruiz-Soto R.
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [Abstract] [Full Text] [Related]

  • 3. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ.
    J Clin Oncol; 2017 Apr 01; 35(10):1112-1118. PubMed ID: 28029313
    [Abstract] [Full Text] [Related]

  • 4. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN.
    Gynecol Oncol; 2020 May 01; 157(2):379-385. PubMed ID: 32081463
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ.
    Gynecol Oncol; 2018 Oct 01; 151(1):46-52. PubMed ID: 30093227
    [Abstract] [Full Text] [Related]

  • 7. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
    Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ.
    Future Oncol; 2018 Jan 01; 14(2):123-136. PubMed ID: 29098867
    [Abstract] [Full Text] [Related]

  • 8. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
    Kokori E, Olatunji G, Komolafe R, Abraham IC, Ukoaka B, Samuel O, Ayodeji A, Ogunbowale I, Ezenwoba C, Aderinto N.
    Medicine (Baltimore); 2024 May 17; 103(20):e38132. PubMed ID: 38758856
    [Abstract] [Full Text] [Related]

  • 9. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ.
    Cancer; 2017 Aug 15; 123(16):3080-3087. PubMed ID: 28440955
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
    Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK.
    Clin Cancer Res; 2019 Mar 15; 25(6):1727-1736. PubMed ID: 30413525
    [Abstract] [Full Text] [Related]

  • 12. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
    Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T, Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups.
    N Engl J Med; 2023 Dec 07; 389(23):2162-2174. PubMed ID: 38055253
    [Abstract] [Full Text] [Related]

  • 13. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
    Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM.
    Mol Cancer Ther; 2015 Jul 07; 14(7):1605-13. PubMed ID: 25904506
    [Abstract] [Full Text] [Related]

  • 14. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
    Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ.
    Future Oncol; 2018 Jul 07; 14(17):1669-1678. PubMed ID: 29424243
    [Abstract] [Full Text] [Related]

  • 15. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ.
    Gynecol Oncol; 2017 Nov 07; 147(2):402-407. PubMed ID: 28843653
    [Abstract] [Full Text] [Related]

  • 16. Folate Receptor α-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.
    Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y.
    Mol Pharm; 2019 Sep 03; 16(9):3996-4006. PubMed ID: 31369274
    [Abstract] [Full Text] [Related]

  • 17. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ.
    Ann Oncol; 2021 Jun 03; 32(6):757-765. PubMed ID: 33667670
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM.
    Gynecol Oncol; 2023 Mar 03; 170():241-247. PubMed ID: 36736157
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
    Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL.
    Invest New Drugs; 2021 Apr 03; 39(2):509-515. PubMed ID: 32984932
    [Abstract] [Full Text] [Related]

  • 20. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
    Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ.
    Int J Gynecol Cancer; 2024 Apr 01; 34(4):469-477. PubMed ID: 38101816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.